Nurix Therapeutics (NRIX) EBIT Margin (2019 - 2026)
Nurix Therapeutics (NRIX) posted quarterly EBIT Margin of 1041.73% for Q2 2026, down 93205.0% year-over-year from N/an in Q2 2025, and up 29.59% quarter-over-quarter from 1479.45% in Q1 2026.
Powered by 
Analysis
Nurix Therapeutics (NRIX) EBIT Margin (2019 - 2026) Analysis & Trends
Nurix Therapeutics (NRIX) has reported EBIT Margin for 8 consecutive years, with 1041.73% the latest figure, recorded in Q2 2026.
- In Q2 2026, EBIT Margin fell 93205.0% year-over-year to 1041.73%; the TTM figure through May 2026 stood at 982.37% (down 72162.0% YoY), while the FY2025 annual figure was 340.16%, up 5036.0% from the prior year.
- EBIT Margin climbed to 1041.73% in Q2 2026 per NRIX's latest filing, from 1479.45% in the prior quarter.
- Across five years, EBIT Margin topped out at 87.25% in Q2 2023 and bottomed at 1479.45% in Q1 2026.
- Historically, EBIT Margin has averaged 515.13% across 5 years, with a median of 417.18% in 2022.
- Annual changes were most pronounced in 2023 — EBIT Margin jumped 41877 bps — and 2026, when it plunged 113878 bps.
- Nurix Therapeutics' EBIT Margin stood at 717.82% in 2022, then surged by 58 bps to 299.06% in 2023, then plunged by 63 bps to 486.73% in 2024, then declined by 26 bps to 612.03% in 2025, then slumped by 70 bps to 1041.73% in 2026.
- Business Quant data shows NRIX's EBIT Margin at 1041.73% in Q2 2026, 1479.45% in Q1 2026, and 612.03% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Nurix Therapeutics | 2.90 Bn | 2.46 Bn | - | -1,041.73% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| May 31, 2026 | -1,041.73% |
| Feb 28, 2026 | -1,479.45% |
| Nov 30, 2025 | -612.03% |
| Aug 31, 2025 | -1,157.65% |
| May 31, 2025 | -109.68% |
| Feb 28, 2025 | -340.67% |
| Nov 30, 2024 | -486.73% |
| Aug 31, 2024 | -433.83% |
| May 31, 2024 | -401.42% |
| Feb 29, 2024 | -272.65% |
| Nov 30, 2023 | -299.06% |
| Aug 31, 2023 | -216.67% |
| May 31, 2023 | -87.25% |
| Feb 28, 2023 | -338.60% |
| Nov 30, 2022 | -717.82% |
| Aug 31, 2022 | -432.93% |
| May 31, 2022 | -399.89% |
| Feb 28, 2022 | -444.28% |
| Nov 30, 2021 | -513.16% |
| Aug 31, 2021 | -282.84% |